Peptide News Digest

Petrelintide ZUPREME-2 Results, WHO's First Child Obesity Guidelines, SurVaxM Glioblastoma Vaccine Trial

Zealand's petrelintide cuts weight up to 9.2% in type 2 diabetes, WHO advises against obesity drugs under age 10, and SurVaxM misses its survival goal.

8 stories · Covering clinical-trials, regulatory, research

Editor's Note

Wednesday's obesity news moved at two speeds. Zealand's amylin drug petrelintide cut weight in people with type 2 diabetes, with few dropouts for stomach side effects. A lab-made Chinese copy of semaglutide matched Wegovy, and starts of the Wegovy pill briefly passed those of the injected form within three months of approval. The World Health Organization was more cautious about young people: its first child and teen obesity guidelines advise against drugs under age 10 and allow them for teens only after a supervised lifestyle program fails. A Swiss case report showed where some demand goes instead, after a life coach injected a young woman with an unverified product sold as retatrutide, a drug no regulator has approved. Outside obesity, MimiVax's survivin vaccine missed its main goal in glioblastoma, and its better result in patients 65 and under needs a new trial to confirm it. Two lab papers used AI to design short antimicrobial peptides and used a ring-shaped peptide to carry antibodies into the brains of mice.

Clinical Trials

Zealand's Amylin Analog Petrelintide Cuts Weight Up to 9.2% vs 2.0% on Placebo at 28 Weeks in Phase 2 ZUPREME-2 Trial in Type 2 Diabetes

Zealand Pharma reported topline results on October 7, 2026 from ZUPREME-2, a 28-week randomized, double-blind, placebo-controlled Phase 2 trial of once-weekly petrelintide in 220 U.S. adults with overweight or obesity and type 2 diabetes, who started with an average BMI of 36.3 and HbA1c of 8.0%. Across three dose groups, average weight fell 7.4% to 9.2% versus 2.0% on placebo, measured as if everyone had stayed on treatment, and HbA1c fell by up to 0.65 percentage points while it rose 0.23 points on placebo. Only 1.9% of people on petrelintide stopped because of stomach side effects, versus 1.7% on placebo; the drug, partnered with Roche, entered Phase 3 in September, and Zealand plans to present full results at a scientific meeting.

#petrelintide #zealand-pharma #amylin #type-2-diabetes #roche
Regulatory

WHO's First Guidelines on Child and Adolescent Obesity Advise Against Weight-Loss Drugs Under Age 10 and Allow Them for Teens Only After Lifestyle Programs Fail

The World Health Organization published its first guidelines on managing obesity in children and in adolescents on October 7, 2026. For children up to age 9, it makes a strong recommendation against weight-loss medicines, based on low-quality evidence. For ages 10 to 19, it conditionally suggests medicines only for teens who have obesity-related complications, such as type 2 diabetes or uncontrolled high blood pressure, and whose weight has not improved after a supervised diet, exercise, and behavior program lasting at least six months; treatment should be given by a specialist team with long-term follow-up. WHO's evidence review found mostly short trials and noted that teens taking GLP-1 drugs or orlistat stopped more often because of side effects.

#pediatric-obesity #who-guideline #glp-1 #obesity
Clinical Trials

MimiVax's Survivin Peptide Vaccine SurVaxM Misses Its Overall Survival Goal in Phase 2b Glioblastoma Trial but Does Better in Patients 65 and Under

MimiVax and Roswell Park Comprehensive Cancer Center reported on October 7, 2026 that in SURVIVE, a randomized, double-blind, placebo-controlled Phase 2b trial in 233 evaluable patients with newly diagnosed glioblastoma at 11 U.S. centers, adding SurVaxM to standard treatment gave a median overall survival of 22.8 months versus 20.3 months on placebo (hazard ratio 0.75, p=0.076), short of statistical significance. In a prespecified group of patients 65 and under, median survival was 24.2 versus 20.2 months (hazard ratio 0.64, p=0.019), and about 42% versus 18% were alive at 30 months or later. SurVaxM is a peptide-mimic vaccine aimed at survivin, a protein found in about 95% of glioblastomas; grade 3 or higher side effects occurred in 48% versus 46% of patients, and MimiVax plans to ask the FDA about faster approval routes.

#survaxm #glioblastoma #cancer-vaccine #peptide-vaccine #mimivax
Clinical Trials

CSPC's Chemically Synthesized Semaglutide HD1916 Matches Wegovy on Weight Loss in a 462-Person Phase 3 Trial in China

A Phase 3 trial published October 7, 2026 in Diabetes, Obesity and Metabolism randomized 462 Chinese adults with obesity (BMI of 28 or higher) and no diabetes at 30 centers to once-weekly HD1916, a semaglutide made by chemical synthesis instead of in yeast, or to Novo Nordisk's Wegovy for 44 weeks. Weight fell 13.1% with HD1916 and 14.4% with Wegovy, a 1.35-percentage-point gap that stayed inside the preset equivalence margin of 4.16 points, and 87.8% versus 90.5% lost at least 5% of their body weight. The open-label trial was sponsored by the drug's developer, CSPC Baike (Shandong) Biopharmaceutical, whose employees are among the authors; side effects of any grade occurred in 86.5% and 89.2% of participants, mostly mild to moderate.

#semaglutide #generic-semaglutide #china #cspc-pharmaceuticals #wegovy
Research

Wegovy Pill Starts Briefly Passed Injectable Semaglutide Within Three Months of Approval, Penn Analysis of 47.9 Million U.S. Health Records Finds

University of Pennsylvania researchers reported in JAMA Network Open on October 7, 2026 that among 47.9 million adults eligible for obesity medicines in Epic Cosmos, a database of health records from more than 2,000 U.S. hospitals, 148,792 started oral semaglutide between December 22, 2025, when the FDA approved the pill for obesity, and March 15, 2026: 87.6% on the Wegovy pill and 12.4% on Rybelsus. Weekly starts peaked at 4.56 per 10,000 eligible adults in early March, briefly exceeding starts of injectable semaglutide, and 53.0% of people starting the pill had never used a GLP-1 drug before. Compared with people starting injections, pill users were older on average, more often women (72.7%), and had a lower average BMI (36.6); the study counted prescription orders, which may not all have been filled.

#oral-semaglutide #wegovy-pill #real-world-evidence #epic-cosmos
Research

Zurich Doctors Report a Woman Hospitalized With Days of Vomiting After a Life Coach Injected an Unverified 'Retatrutide' Product

Physicians at University Hospital Zurich described in BMJ Case Reports on October 7, 2026 a woman in her mid-20s who was admitted after five days of nausea, repeated vomiting, and loose stools that did not stop with IV fluids and three anti-nausea drugs. After repeated questioning, she said that in a wellness setting a self-described life coach with no medical training had given her four weekly, rising doses of an unverified product said to contain retatrutide, Eli Lilly's experimental GLP-1, GIP, and glucagon drug; she had not thought of the shots as medicine. She improved two days after admission and recovered within a week, a standard scale rated the product as the probable cause, and the authors urge doctors to ask directly about injections, peptides, and research chemicals.

#retatrutide #gray-market #wellness #side-effects
Research

SMAMP Deep-Learning Model Designs Chemically Modified Ultrashort Antimicrobial Peptides That Protected Infected Larvae and Aided Wound Healing in Mice

Researchers at Zhejiang University of Technology in China and Egypt's National Research Centre reported in the Journal of Medicinal Chemistry on October 7, 2026 a deep-learning model, SMAMP, that reads peptides as full chemical structures, so it can handle unnatural amino acids and end-group changes that sequence-based models miss. Of 19 very short peptides designed with its help, 13 killed bacteria, and the model's predicted potency against E. coli tracked lab measurements (correlation 0.764). Two leads, HP-1 and HP-2, were strongly bactericidal with low toxicity to mammalian cells, led to less resistance than standard antibiotics in lab tests, protected wax moth larvae from infection, and helped wounds heal in mice.

#antimicrobial-peptides #ai-drug-design #antibiotic-resistance #preclinical
Research

Kumamoto University Team Fuses a Small Cyclic Peptide to Antibodies to Raise Their Brain Levels in Mice

Researchers at Kumamoto University in Japan reported in Molecular Pharmaceutics on October 7, 2026 a small ring-shaped peptide, called SLS, that can be built into an antibody's genetic code to help it reach the brain. Attaching one SLS peptide to each heavy chain of the breast cancer antibody trastuzumab increased its passage across lab models of the blood-brain barrier and raised its brain levels after intravenous injection in mice, while its blood levels and its ability to kill HER2-positive cancer cells stayed about the same. The tag also raised brain delivery of the Alzheimer's antibody aducanumab; the work so far is in cells and mice.

#blood-brain-barrier #cyclic-peptide #drug-delivery #preclinical

Related Guides